April 18, 2018 9:15 AM
Decision Diagnostics (DECN) Contemplates Additional Legal Actions Against Longtime Adversary Johnson & Johnson (JNJ)
LOS ANGELES, CA / ACCESSWIRE / April 18, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine"
diabetes test strip, the internationally launched GenSure! ("Feather" diabetes test strip, and the clinical trial ready GenChoice! ("Ladybug" and the panacea GenPrecis! ("Dragonfly" diabetes testing system. Today the Company announced it is contemplating the pendency of additional legal proceedings in Federal court against Johnson and Johnson (JNJ) in addition to the current patent litigation.
J&J's contemplated near-term sale of its Lifescan divisions (the subject of the current lawsuits), for which there is a firm offer by a major investor, raises potential issues of J&J trying to escape the judgment of millions of dollars of damages brought against them in our current patent infringement suit.
Keith Berman, CEO, who has successfully litigated and settled patent matters with Johnson and Johnson and their divisions Lifescan, Inc. and Lifescan Scotland Ltd., and who has a potential nine figure suit filed in U.S. District Court, District of Nevada, is guiding the DECN companies as they endeavor to keep J&J and its divisions from "escaping the hangman's noose." It is for this reason, the company has decided to add additional litigation counsel to strike against J&J and its divisions in an effort to bar J&J's potential escape from the massive infringement damages that underlie the patent infringement suit.
The Company cannot comment on any additional details at this time, but will keep shareholders and investors informed as the due diligence process is rolled out. Mr. Berman said, "Although we are focused on successfully completing current litigation for the benefit of the company and its shareholders, we may have an additional case that, upon further validation, could lead to a speedier outcome for us all."
Mr. Berman concluded, "It has been and is our intent to always protect our assets and growth prospects by litigating only the cases that are plausible and weigh in our favor. Whenever these M&A transactions arise, oftentimes they are used to sweep past transgressions under the carpet. It is in our best interests not to let this happen."
For more information on the Company and updates on the litigation process please visit the company websites: www.decisiondiagnostics.co and www.pharmatechsolutions.co.
ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 6 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $12 billion market.
Forward-Looking Statements:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of April 16, 2018, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
CONTACT INFORMATION:
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
Joanne Broeders (305) 340-1000
info@decisiondiagnostics.com
www.genultimate.com
www.pharmatechdirect.com
SOURCE: Decision Diagnostics Corp.
News Provided by ACCESSWIRE via QuoteMedia
Decision Diagnostics (DECN) Contemplates Additional Legal Actions Against Longtime Adversary Johnson & Johnson (JNJ)
LOS ANGELES, CA / ACCESSWIRE / April 18, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine"
diabetes test strip, the internationally launched GenSure! ("Feather" diabetes test strip, and the clinical trial ready GenChoice! ("Ladybug" and the panacea GenPrecis! ("Dragonfly" diabetes testing system. Today the Company announced it is contemplating the pendency of additional legal proceedings in Federal court against Johnson and Johnson (JNJ) in addition to the current patent litigation. J&J's contemplated near-term sale of its Lifescan divisions (the subject of the current lawsuits), for which there is a firm offer by a major investor, raises potential issues of J&J trying to escape the judgment of millions of dollars of damages brought against them in our current patent infringement suit.
Keith Berman, CEO, who has successfully litigated and settled patent matters with Johnson and Johnson and their divisions Lifescan, Inc. and Lifescan Scotland Ltd., and who has a potential nine figure suit filed in U.S. District Court, District of Nevada, is guiding the DECN companies as they endeavor to keep J&J and its divisions from "escaping the hangman's noose." It is for this reason, the company has decided to add additional litigation counsel to strike against J&J and its divisions in an effort to bar J&J's potential escape from the massive infringement damages that underlie the patent infringement suit.
The Company cannot comment on any additional details at this time, but will keep shareholders and investors informed as the due diligence process is rolled out. Mr. Berman said, "Although we are focused on successfully completing current litigation for the benefit of the company and its shareholders, we may have an additional case that, upon further validation, could lead to a speedier outcome for us all."
Mr. Berman concluded, "It has been and is our intent to always protect our assets and growth prospects by litigating only the cases that are plausible and weigh in our favor. Whenever these M&A transactions arise, oftentimes they are used to sweep past transgressions under the carpet. It is in our best interests not to let this happen."
For more information on the Company and updates on the litigation process please visit the company websites: www.decisiondiagnostics.co and www.pharmatechsolutions.co.
ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 6 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $12 billion market.
Forward-Looking Statements:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of April 16, 2018, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
CONTACT INFORMATION:
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
Joanne Broeders (305) 340-1000
info@decisiondiagnostics.com
www.genultimate.com
www.pharmatechdirect.com
SOURCE: Decision Diagnostics Corp.
News Provided by ACCESSWIRE via QuoteMedia
3
